Exploring the Correlation Between MRI Image Characteristics and Diagnosis, Pathology and Prognosis in Patients With Prostate Lesions

Launched by ZHEN LI · Apr 20, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how MRI (Magnetic Resonance Imaging) can help doctors better understand and diagnose prostate lesions, especially concerning prostate cancer. Prostate cancer is a common and serious condition that affects many men, and traditional methods of diagnosis, like biopsies, can sometimes lead to unnecessary procedures and stress for patients. The trial aims to improve the accuracy of diagnoses by analyzing MRI images in detail, helping to distinguish between benign (non-cancerous) and malignant (cancerous) lesions. By using advanced imaging techniques, researchers hope to provide clearer insights into the nature of prostate lesions, which can lead to better treatment decisions and outcomes for patients.

To be eligible for this trial, participants should be adult males with elevated prostate-specific antigen (PSA) levels or abnormal results from exams like digital rectal exams or imaging tests. They should be willing to take part in the study and sign a consent form. However, individuals with certain medical devices (like pacemakers) or those who have recently received specific cancer treatments will not be able to participate. Participants can expect to undergo detailed MRI scans and may contribute to important research that could help improve prostate cancer diagnosis and treatment in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with abnormal prostate-specific antigen (PSA) elevated (\>4.0 ng/ml) or abnormal digital rectal examination (DRE) or suspicious lesions found by prostate ultrasound, CT or MRI in the hospital
• • 2. Age/Gender: Adult male
• • 3. Patients who voluntarily participate in clinical trials and sign a written informed consent form for subjects
• Exclusion Criteria:
• • 1. Patients with pacemakers, unknown materials, metal implants in the body, neurostimulators, and claustrophobia
• • 2. Patients who underwent biopsy, local ablation, prostate surgery, or endocrine therapy, chemotherapy, radiotherapy and other anti-tumor treatments before examination